Wellington researchers seek patients aged 40 and over with chronic bronchitis or emphysema for worldwide study
New Zealanders who suffer from chronic obstructive pulmonary disorder (COPD) – which is also known as “chronic
bronchitis,” “smoker’s cough” or emphysema - are being encouraged to participate in a worldwide study that will test a
potential new treatment for the condition.
Wellington researchers at P3 Research Wellington and the Medical Research Institute of New Zealand are joining forces with colleagues around the world to determine whether a potential new treatment can reduce the
frequency of COPD symptoms, keep participants out of hospital and help them better cope with their day-to-day life.
Patients are being sought who:
- Are aged 40+
- Have COPD, chronic bronchitis, smoker’s cough, or emphysema and are taking regular medication for the condition
- Had some worsening in the last 12 months of COPD symptoms that required additional treatment or hospital admission
COPD has a substantial impact on the health of New Zealanders. Although often undiagnosed, it affects an estimated 15
percent of the adult population over the age of 45 years (at least 200 000 New Zealanders).1
Respiratory expert Dr Dean Quinn from P3 Research Wellington welcomed the study and said he hoped New Zealand patients
would take the opportunity to participate.
“There is no cure for COPD which is why it is so important to keep researching new treatment options. We need treatments
that do an effective job in reducing symptoms, keep people out of hospital and improve their quality of life,” said Dr
Quinn.
“Participating in a research study can also be beneficial for the participants as they receive high quality medical
monitoring and regular health checks at no cost. The patients could do some good for themselves while also helping
progress New Zealand research into new medicines,” concluded Dr Quinn.
Participation in the study is voluntary and information is kept strictly confidential. This study has been approved by
Human Research Ethics Committees to be conducted at various New Zealand centres.
For further information about COPD and upcoming clinical trials you can call 0800 827 840 or visit www.gsk.co.nz/COPD
ENDS